ClinicalTrials.gg
CompletedNCT02585895Updated Nov 30, 2022Results posted

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

A Phase 3 interventional study of Evolocumab and Low-density Lipoprotein Cholesterol (LDL-C) Apheresis in Hypercholesterolemia, sponsored by Amgen. Completed at 17 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
32nd of 36
39 · median 308
Started
2015
the only one that year
Phase 3
22 of 36
none open now
Registered
24th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 32nd largest by enrollment, is the only one that started in 2015, is one of 22 in phase 3, and was the 24th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • LDL-C Apheresis
  • Hypercholesterolemia
  • Elevated Cholesterol
  • High Cholesterol
  • PCSK9 mutations
  • Severe Familial Hypercholesterolemia
  • evolocumab
  • Repatha
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ≥ 18 years of age
  • Subject has been receiving regular apheresis for LDL-C lowering for at least 3 months immediately prior to lipid screening and has a treatment goal of LDL-C \< 100 mg/dL (2.6 mmol/L), and has been receiving LDL-C apheresis during the last ≥ 4 weeks prior to lipid screening at regular QW or Q2W schedule and with no changes in apheresis type
  • Subject is receiving lipid-lowering pharmacological background therapy which includes a high-intensity statin dose (moderate-intensity statin dose with attestation that a higher dose is not appropriate for the subject) unless the subject has a history of statin intolerance
  • Lipid-lowering therapy status (ie, any therapy for lowering lipids, including apheresis type and frequency) must be unchanged for ≥ 4 weeks prior to LDL-C screening
  • Pre-apheresis LDL-C is ≥ 100 mg/dL (≥ 2.6 mmol/L) and ≤ 190 mg/dL (≤ 4.9 mmol/L) at screening
  • Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) at screening.

Exclusion criteria

Exclusion criteria:

  • Known homozygous familial hypercholesterolemia
  • Missing any apheresis session is medically or inappropriate
  • Stopping apheresis would be inappropriate in the opinion of the investigator even if LDL-C is controlled to \< 100 mg/dL with other therapies
  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization.
  • Uncontrolled hypertension
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.

    Biological: Evolocumab

  • Active comparator
    Low Density Lipoprotein Cholesterol (LDL-C) Apheresis

    Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.

    Biological: Evolocumab · Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection once every 2 weeks

    Also known as: Repatha, AMG 145

  • ProcedureLow-density Lipoprotein Cholesterol (LDL-C) Apheresis

    Participants received apheresis for LDL-C according the their physician's prescription and local custom.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy

    Avoidance of apheresis at end of randomized therapy was defined as no apheresis at week 5 and week 6. Aperesis at weeks 5 or 6 was based on LDL-C level at week 4: participants with LDL-C ≥ 100 mg/dL at week 4 received apheresis at week 5 (participants who received apheresis QW before study entry) or week 6 (participants who received apheresis Q2W prior to study entry). If LDL-C was \< 100 mg/dL at week 4, no apheresis was performed at week 5 or week 6, irrespective of assigned treatment group. Participants who ended the study prior to week 6 were considered as not achieving apheresis avoidance.

    Time frame: Week 5 and week 6

Secondary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol

    Time frame: Baseline and week 4

  2. Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol

    Time frame: Baseline and Week 4

  3. Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio

    Time frame: Baseline and Week 4

07

Results

Posted Sep 19, 2017

Participant flow

This study was conducted at 15 centers in the following 8 countries: Australia, Czech Republic, France, Germany, Italy, Spain, the United Kingdom, and the United States. Participants were enrolled from 21 December 2015 to 21 July 2016.

Primary Period
Participant flow — Primary Period
MilestoneApheresisEvolocumab
Started2019
Completed2019
Not completed00
Post-primary Period
Participant flow — Post-primary Period
MilestoneApheresisEvolocumab
Started2019
Completed2019
Not completed00

Outcome measures

PrimaryPercentage of Participants With Apheresis Avoidance at the End of Randomized Therapy

Avoidance of apheresis at end of randomized therapy was defined as no apheresis at week 5 and week 6. Aperesis at weeks 5 or 6 was based on LDL-C level at week 4: participants with LDL-C ≥ 100 mg/dL at week 4 received apheresis at week 5 (participants who received apheresis QW before study entry) or week 6 (participants who received apheresis Q2W prior to study entry). If LDL-C was \< 100 mg/dL at week 4, no apheresis was performed at week 5 or week 6, irrespective of assigned treatment group. Participants who ended the study prior to week 6 were considered as not achieving apheresis avoidance.

Time frame:
Week 5 and week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy
percentage of participantsApheresisEvolocumab
Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy10.0 (2.8 to 30.1)84.2 (62.4 to 94.5)
Statistical analysis
  • Apheresis vs Evolocumab · Cochran-Mantel-Haenszel · p = < 0.0001 · Treatment difference: 74.2 · 95% CI 44.6 to 86.8Treatment difference used apheresis as the reference.
SecondaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol
Time frame:
Baseline and week 4
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol
percent changeApheresisEvolocumab
Percent Change From Baseline in Low-density Lipoprotein Cholesterol2.61 ± 3.97-50.13 ± 4.03
Statistical analysis
  • Apheresis vs Evolocumab · Repeated measures linear effects model · p = < 0.0001 · Treatment difference: -52.74 · 95% CI -64.18 to -41.30Treatment difference used apheresis as the reference.
SecondaryPercent Change From Baseline in Non-high-density Lipoprotein-Cholesterol
Time frame:
Baseline and Week 4
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol
percent changeApheresisEvolocumab
Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol1.80 ± 3.29-44.58 ± 3.34
Statistical analysis
  • Apheresis vs Evolocumab · Repeated measures linear effects model · p = < 0.0001 · Treatment difference: -46.37 · 95% CI -55.85 to -36.90Treatment difference used apheresis as the reference.
SecondaryPercent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio
Time frame:
Baseline and Week 4
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio
percent changeApheresisEvolocumab
Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio0.15 ± 2.65-35.65 ± 2.67
Statistical analysis
  • Apheresis vs Evolocumab · Repeated measures linear effects model · p = < 0.0001 · Treatment difference: -35.80 · 95% CI -43.39 to -28.21Model included treatment group, screening LDL-C level, scheduled visit, and the interaction of treatment group with scheduled visit as covariates.

Adverse events

Collected over 6 weeks during the primary period and 20 weeks during the post-primary period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primary Period: Apheresis QW—0/4 (0%)2/4 (50%)
Primary Period: Apheresis Q2W—2/16 (12.5%)5/16 (31.3%)
Primary Period: Evolocumab—0/19 (0%)10/19 (52.6%)
Post-primary Period: Apheresis/Evolocumab—0/20 (0%)6/20 (30%)
Post-primary Period: Evolocumab/Evolocumab—2/19 (10.5%)8/19 (42.1%)
Most frequent serious events
Most frequent serious events
EventPrimary Period: Apheresis QWPrimary Period: Apheresis Q2WPrimary Period: EvolocumabPost-primary Period: Apheresis/EvolocumabPost-primary Period: Evolocumab/Evolocumab
Myocardial ischaemiaCardiac disorders0/41/160/190/200/19
Respiratory failureRespiratory, thoracic and mediastinal disorders0/41/160/190/200/19
Retinal vein occlusionEye disorders0/40/160/190/201/19
Benign prostatic hyperplasiaReproductive system and breast disorders0/40/160/190/201/19
Most frequent other events
Showing 10 of 46
Most frequent other events
EventPrimary Period: Apheresis QWPrimary Period: Apheresis Q2WPrimary Period: EvolocumabPost-primary Period: Apheresis/EvolocumabPost-primary Period: Evolocumab/Evolocumab
Tooth abscessInfections and infestations1/40/160/191/200/19
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/40/160/190/200/19
MyalgiaMusculoskeletal and connective tissue disorders0/41/162/191/200/19
HeadacheNervous system disorders0/40/162/192/201/19
RashSkin and subcutaneous tissue disorders0/40/162/190/201/19
DiarrhoeaGastrointestinal disorders0/40/160/192/201/19
NauseaGastrointestinal disorders0/40/160/192/200/19
FatigueGeneral disorders0/40/161/192/200/19
Influenza like illnessGeneral disorders0/40/160/192/200/19
Myocardial ischaemiaCardiac disorders0/41/160/190/200/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)ApheresisEvolocumabTotal
Mean59.6 ± 10.065.4 ± 8.162.4 ± 9.5
Age, Customized
Age, Customized(participants)ApheresisEvolocumabTotal
< 65 years14721
≥ 65 years61218
Sex: Female, Male
Sex: Female, Male(Participants)ApheresisEvolocumabTotal
Female7916
Male131023
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ApheresisEvolocumabTotal
Hispanic or Latino022
Not Hispanic or Latino201737
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ApheresisEvolocumabTotal
American Indian or Alaska Native000
Asian000
Black or African American011
Native Hawaiian or Other Pacific Islander000
White201838
Stratification Factor: Screening LDL-C Level
Stratification Factor: Screening LDL-C Level(participants)ApheresisEvolocumabTotal
< 160 mg/dL111122
≥ 160 mg/dL9817
LDL-C Concentration
LDL-C Concentration(mg/dL)ApheresisEvolocumabTotal
Mean150.6 ± 25.6152.4 ± 21.2151.5 ± 23.3
08

Study locations

17 sites
  • Research Site
    Boca Raton, Florida 33434, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Grandville, Michigan 49418, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Heidelberg, Victoria 3084, Australia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Bron, 69677, France
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Düsseldorf, 40210, Germany
  • Research Site
    Flensburg, 24939, Germany
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Sevilla, Andalucía 41013, Spain
  • Research Site
    Harefield, UB9 6JH, United Kingdom
  • Research Site
    Penarth, CF64 2XX, United Kingdom
09

References and documents

Publications

  • Baum SJ, Sampietro T, Datta D, Moriarty PM, Knusel B, Schneider J, Somaratne R, Kurtz C, Hohenstein B. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. J Clin Lipidol. 2019 Nov-Dec;13(6):901-909.e3. doi: 10.1016/j.jacl.2019.10.003. Epub 2019 Oct 11. PubMed 31759938 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Sep 2016, 8 months.

Results were first posted in Sep 2017, 1 year after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2015
First posted
Oct 26, 2015
StartActual
Dec 21, 2015
Primary completionActual
Sep 1, 2016
CompletionActual
Jan 20, 2017
Results first posted
Sep 19, 2017
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02585895
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 26, 2015
Start date
Dec 21, 2015
Primary completion
Sep 1, 2016
Completion
Jan 20, 2017
Results posted
Sep 19, 2017
Last update
Nov 30, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion